ArticleBioengineering & translational medicine2026
Human induced pluripotent stem cell-derived mesenchymal stromal cells regenerate diabetic ischemic muscle.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic limb threatening ischemia (CLTI), the most severe stage of peripheral arterial disease, affects over 500,000 patients in the United States and is associated with a 25% annual risk of amputation. Diabetic CLTI patients experience exceedingly high rates of lower extremity amputation. Many of these patients fail or are not suitable for revascularization, yet no effective non-surgical therapies exist for this population. This study examined how human induced pluripotent stem cell (hiPSC)-derived mesenchymal stromal cells (MSC) interrupt ischemic limb changes and stimulate muscle regeneration in a diabetic murine CLTI model. Mice treated with hiPSC-MSC demonstrated muscle regeneration, angiogenesis, and decreased inflammation. RT-qPCR expression of embryonic myosin heavy chain 3 (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.